Drug
BI 1820237 clinical trials
Also written BI 1820237.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BI 1820237 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityCompletedPhase 1Boehringer IngelheimNCT06352424Written as BI 1820237
- A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906CompletedPhase 1Boehringer IngelheimNCT05751226Written as BI 1820237
- A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With LiraglutideCompletedPhase 1Boehringer IngelheimNCT04903509Written as BI 1820237